Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations

Next Previous
X
Search
Trial Profile

LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms LUX-LUNG-2
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 16 Jan 2018 According to a Boehringer Ingelheim media release, based on a pooled analysis of LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 studies the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Gilotrif (afatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have non-resistant epidermal growth factor receptor mutations as detected by an FDA-approved test. The FDA granted Priority Review status to the application.
    • 24 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Oct 2013 Planned end date changed from 1 Jul 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top